Showing results (1-10 of 41) with videos related to
Sort By:
Pageof 5
Pulmonary Pharmacology & Therapeutics|September 30, 2022
May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?Ralph Brattsand, Olof SelroosPharmaceuticals (Basel, Switzerland)|April 27, 2024
Budesonide Attains Its Wide Clinical Profile by Alternative KineticsRalph Brattsand, Olof SelroosSarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|September 24, 2024
Inhaled budesonide and pulmonary sarcoidosis revisitedOlof Selroos, Ralph BrattsandTherapeutics and Clinical Risk Management|March 25, 2008
A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroidOlof SelroosRespiratory Medicine|April 5, 2008
Effect of disease duration on dose-response of inhaled budesonide in asthmaOlof SelroosCurrent Medical Research and Opinion|October 7, 2004
The place of inhaled corticosteroids in chronic obstructive pulmonary diseaseOlof SelroosPulmonary Pharmacology & Therapeutics|July 2, 2002
Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilationOlof Selroos, Tommy EkströmTherapeutic Advances in Respiratory Disease|May 16, 2009
Use of dry powder inhalers in acute exacerbations of asthma and COPDOlof Selroos, Lars Borgström, Jarl IngelfAnnals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 28, 2002
Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available dataStaffan Edsbäcker, Ralph BrattsandPageof 5